Skip to main content

NY Court Denies A Talc Supplier's Summary Judgment Motion

NY Court Denies A Talc Supplier's Summary Judgment Motion

NY Court Denies A Talc Supplier's Summary Judgment Motion

Introduction

In an order issued on October 5, 2018, the New York Supreme Court for the New York County denied a summary judgment motion to Whittaker, Clark & Daniel in a talcum powder lawsuit related to hazards of asbestos exposure.

The Supreme Court judge asserted that the plaintiffs submitted sufficient evidence to support the claims over inadequate warning about cancer effects of asbestos-laden talcum powder. The order stated proof of shipment from the defendant to a cosmetic talcum powder company is enough to hold the talc supplier liable in the case. The judge further clarified, "the facts provided by the plaintiff raise genuine triable issues of fact requiring that the motion is denied.”

Talcum powder manufacturers are facing hundreds of product liability cases across the nation over allegations that asbestos presence in talcum powder cause mesothelioma and ovarian cancer. The defendant companies are Johnson & Johnson, Colgate-Palmolive, Imerys Talc North America, Vanderbilt Minerals.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Second Valsartan Cancer Trials Set for Early 2026

Categories: Valsartan

As the first federal bellwether trial involving Valsartan cancer lawsuits approaches this fall, the U.S. District Judge overseeing the litigation has signaled that a…

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!